Drug Approval | March 22, 2025
SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Morepen Laboratories approves hiving off of medical devices business
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
